(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Headache Disorder
Explore 13 assets in Headache Disorder →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05306899CT.gov Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | — | Recruiting | — | — | — |
NCT02657031CT.gov The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine | — | Completed | — | — | — |
NCT02697071CT.gov Ketamine for Acute Migraine in the Emergency Department | — | Completed | — | — | — |
NCT02403687CT.gov Prospective Analgesic Compound Efficacy (PACE) Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Headache Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | University Health Network, Toronto | Approved | BB · 69 |
| Topiramate | University of Minnesota | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | Danish Headache Center | P4 | BBB |
| Lidocaine | Daniel A Tonetti, MD | P4 | BBB |
| Prochlorperazine | Wake Forest University Health Sciences | P4 | BBB |
| Propofol | Medical College of Wisconsin | P4 | BBB |
| Marcaine | HCA Florida North Florida Hospital | P4 | BBB |
| Naproxen | Ache Laboratorios Farmaceuticos S.A. | P4 | BBB |
| Amitriptyline | Children's Hospital Medical Center, Cincinnati | P4 | BB |
+42 more in the Headache Disorder cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Headache Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-headache-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →